Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1016/j.annonc.2020.07.014 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group |
| https://doi.org/10.1093/annonc/mdz116 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach |
| https://doi.org/10.1093/annonc/mdx175 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
| https://doi.org/10.1093/annonc/mdy263 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) |
| https://doi.org/10.1093/annonc/mdx310 | ESMO-Magnitude of Clinical Benefit Scale version 1.1 |
| https://doi.org/10.1093/annonc/mdx221 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours |
| https://doi.org/10.1016/j.annonc.2022.05.520 | ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group |
| https://doi.org/10.1093/annonc/mdx738 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS |
| https://doi.org/10.1200/go.20.00639 | Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review |
| https://doi.org/10.1136/ijgc-2019-000308 | ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease |
| https://doi.org/10.1093/annonc/mdx757 | European Society for Medical Oncology (ESMO) position paper on supportive and palliative care |
| https://doi.org/10.1038/s41592-023-02151-z | Metrics reloaded: recommendations for image analysis validation |
| https://doi.org/10.1093/annonc/mdz204 | ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research |
| https://doi.org/10.1111/jan.14855 | Artificial intelligence in nursing: Priorities and opportunities from an international invitational think‐tank of the Nursing and Artificial Intelligence Leadership Collaborative |
| https://doi.org/10.1016/j.ejca.2013.11.012 | Policy statement on multidisciplinary cancer care |
| https://doi.org/10.1136/esmoopen-2017-000285 | Global cancer control: responding to the growing burden, rising costs and inequalities in access |
| https://doi.org/10.1093/annonc/mdy554 | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS |
| https://doi.org/10.1016/j.annonc.2023.05.008 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer |
| https://doi.org/10.1093/annonc/mdy498 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
| https://doi.org/10.1016/j.annonc.2023.10.125 | Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review |
| https://doi.org/10.1016/j.esmoop.2021.100096 | Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) |
| https://doi.org/10.1093/annonc/mdz136 | Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group |
| https://doi.org/10.1016/j.annonc.2019.12.001 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO |
| https://doi.org/10.1093/annonc/mdy502 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
| https://doi.org/10.1093/annonc/mdy423 | Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) |
| https://doi.org/10.1093/annonc/mdy321 | Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up” |
| https://doi.org/10.1016/s1470-2045(18)30681-8 | National cancer control plans: a global analysis |
| https://doi.org/10.1016/j.breast.2020.02.003 | The requirements of a specialist breast centre |
| https://doi.org/10.1016/j.annonc.2023.10.001 | ESMO Guidance for Reporting Oncology real-World evidence (GROW) |
| https://doi.org/10.1093/annonc/mdp581 | Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative |
| https://doi.org/10.1016/j.annonc.2022.11.013 | Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up |
| https://doi.org/10.1016/j.annonc.2022.07.1941 | ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe |
| https://doi.org/10.1038/s41592-023-02150-0 | Understanding metric-related pitfalls in image analysis validation |
| https://doi.org/10.1016/j.annonc.2020.03.299 | JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions |
| https://doi.org/10.1136/esmoopen-2016-000097 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 |
| https://doi.org/10.1016/j.critrevonc.2016.12.002 | ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review |
| https://doi.org/10.1016/j.annonc.2022.12.003 | Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations |
| https://doi.org/10.1093/annonc/mdu217 | Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO) |
| https://doi.org/10.1200/jco.18.00729 | Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score |
| https://doi.org/10.1016/j.annonc.2020.11.021 | ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research |
| https://doi.org/10.1136/esmoopen-2016-000142 | Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers |
| https://doi.org/10.1016/j.annonc.2019.10.026 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS |
| https://doi.org/10.1016/j.annonc.2019.10.003 | Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer |
| https://doi.org/10.1016/j.annonc.2021.01.068 | The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate |
| https://doi.org/10.1016/j.annonc.2023.06.011 | ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe |
| https://doi.org/10.1016/j.critrevonc.2017.12.019 | ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer |
| https://doi.org/10.1016/j.annonc.2022.09.158 | Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 |
| https://doi.org/10.1136/esmoopen-2020-000826 | ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer |
| https://doi.org/10.1136/esmoopen-2020-000804 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer |
| https://doi.org/10.1016/j.annonc.2021.08.1752 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer |
| https://doi.org/10.1016/j.esmoop.2023.102226 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer |
| https://doi.org/10.1016/j.esmoop.2021.100309 | Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck |
| https://doi.org/10.1136/esmoopen-2016-000127 | The European Cancer Patient’s Bill of Rights, update and implementation 2016 |
| https://doi.org/10.1016/j.esmoop.2023.101558 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer |
| https://doi.org/10.1016/j.esmoop.2022.100744 | Cancer burden in adolescents and young adults in Europe |
| https://doi.org/10.1016/j.esmoop.2021.100117 | Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring |
| https://doi.org/10.1016/j.esmoop.2021.100292 | Distribution of the workforce involved in cancer care: a systematic review of the literature |
| https://doi.org/10.1016/j.critrevonc.2017.12.020 | ECCO essential requirements for quality cancer care: Melanoma |
| https://doi.org/10.1016/j.lungcan.2020.08.017 | European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer |
| https://doi.org/10.1016/j.esmoop.2022.100403 | Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus |
| https://doi.org/10.1016/j.annonc.2023.08.001 | ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) |
| https://doi.org/10.1016/j.annonc.2024.07.730 | The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development |
| https://doi.org/10.1016/j.esmoop.2024.102992 | ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer |
| https://doi.org/10.1016/j.esmoop.2023.101541 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer |
| https://doi.org/10.1016/j.esmoop.2022.100518 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer |
| https://doi.org/10.1016/j.annonc.2022.12.004 | Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit |
| https://doi.org/10.1016/j.annonc.2025.04.006 | ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) |
| https://doi.org/10.1016/j.esmoop.2022.100774 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer |
| https://doi.org/10.1016/j.esmorw.2023.10.001 | ESMO Guidance for Reporting Oncology real-World evidence (GROW) |
| https://doi.org/10.1016/j.esmoop.2024.103647 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer |
| https://doi.org/10.2196/43871 | One Digital Health Intervention for Monitoring Human and Animal Welfare in Smart Cities: Viewpoint and Use Case |
| https://doi.org/10.1016/j.esmoop.2022.100604 | Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines |
| https://doi.org/10.1016/j.annonc.2024.12.005 | ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update |
| https://doi.org/10.1016/j.annonc.2025.06.007 | Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline |
| https://doi.org/10.1016/j.esmoop.2024.103996 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer |
| https://doi.org/10.1007/s12672-023-00636-z | Cardiac dose in the treatment of synchronous bilateral breast cancer patients between three different radiotherapy techniques (VMAT, IMRT, and 3D CRT) |
| https://doi.org/10.1007/s40123-024-00925-y | Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers |
| https://doi.org/10.1016/j.esmoop.2024.102974 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer |
| https://doi.org/10.1016/j.radonc.2025.110910 | ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy |
| https://doi.org/10.1016/j.esmorw.2024.100039 | Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022) |
| https://doi.org/10.1016/j.annonc.2025.06.004 | Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline |
| https://doi.org/10.1016/j.annonc.2025.11.009 | ESMO basic requirements for AI-based biomarkers in oncology (EBAI) |
| https://doi.org/10.1016/j.annonc.2025.09.008 | ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors |
| https://doi.org/10.1016/s1470-2045(25)00520-0 | SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials |
| https://doi.org/10.1016/j.annonc.2025.09.001 | ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP) |
| https://doi.org/10.1016/j.esmoop.2025.105826 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer |
| https://doi.org/10.1093/annonc/mdn101 | Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| https://doi.org/10.1093/annonc/mdi825 | ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer |
| https://doi.org/10.1016/j.critrevonc.2016.12.001 | ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review |
| https://doi.org/10.1093/annonc/mdt522 | The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO) |
| https://doi.org/10.1136/esmoopen-2017-000252 | The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey |
| https://doi.org/10.1016/j.annonc.2020.01.008 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS |
| https://doi.org/10.1093/annonc/mdn083 | Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| https://doi.org/10.1016/j.ctrv.2018.10.001 | Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) |
| https://doi.org/10.1016/j.critrevonc.2019.102861 | ECCO Essential Requirements for Quality Cancer Care: Prostate cancer |
| https://doi.org/10.1093/annonc/mdx280 | The ‘critical mass’ survey of palliative care programme at ESMO designated centres of integrated oncology and palliative care |
| https://doi.org/10.1016/j.annonc.2022.03.273 | Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification |
| https://doi.org/10.1136/esmoopen-2018-000460 | Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology |
| https://doi.org/10.1136/esmoopen-2018-000483 | Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough? |
| https://doi.org/10.5455/aim.2019.27.369-373 | The CrowdHEALTH project and the Hollistic Health Records: Collective Wisdom Driving Public Health Policies |